One of the early events in the progression of LPS-mediated acute lung injury in mice is the disruption of the pulmonary endothelial barrier resulting in lung edema. However, the molecular mechanisms by which the endothelial barrier becomes compromised remain unresolved. The SRY (sex-determining region on the Y chromosome)-related high-mobility group box (Sox) group F family member, SOX18, is a barrier-protective protein through its ability to increase the expression of the tight junction protein CLDN5. Thus, the purpose of this study was to determine if downregulation of the SOX18-CLDN5 axis plays a role in the pulmonary endothelial barrier disruption associated with LPS exposure. Our data indicate that both SOX18 and CLDN5 expression is decreased in two models of in vivo LPS exposure (intraperitoneal, intratracheal). A similar downregulation was observed in cultured human lung microvascular endothelial cells (HLMVECs) exposed to LPS. SOX18 overexpression in HLMVECs or in the mouse lung attenuated the LPS-mediated vascular barrier disruption. Conversely, reduced CLDN5 expression (siRNA) reduced the HLMVEC barrier-protective effects of SOX18 overexpression. The mechanism by which LPS decreases SOX18 expression was identified as transcriptional repression through binding of NF-kB (p65) to a SOX18 promoter sequence located between 21,082 and 21,073 bp with peroxynitrite contributing to LPS-mediated NF-kB activation. We conclude that NF-kB-dependent decreases in the SOX18-CLDN5 axis are essentially involved in the disruption of human endothelial cell barrier integrity associated with LPS-mediated acute lung injury.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by the rapid onset of respiratory insufficiency, resulting in arterial hypoxemia that is refractory to oxygen therapy (1) . ALI is considered to be a less severe form of ARDS with moderate hypoxemia and a Pa O 2 /FI O 2 ratio of less than 300 mm Hg (1). The incidence of ALI has recently been estimated at 86.2 per 100,000 persons per year and its mortality rate at 38.5% (2) . The etiologies of ALI/ARDS are divided into two categories: those that cause direct lung injury and those that cause indirect lung injury by activating a systemic inflammatory response (3) . Of the various risk factors, sepsis is associated with the highest risk of progression to ARDS (4) . Replicating or dying bacteria release antigens into the systemic circulation, including LPS (5), from gram-negative bacteria, triggering a systemic immune response. These microbial products interact with lung endothelial cells lining blood vessels. Vascular endothelial cells exposed to bacterial toxins or inflammatory mediators secrete inflammatory and chemotactic substances, express adhesion molecules, and exhibit a loss of anticoagulant and barrier functions (6) . The loss of pulmonary endothelial barrier function is considered to be a major characteristic of ALI/ARDS pathogenesis. The ensuing plasma extravasation leads to pulmonary edema, the hallmark of ALI/ARDS.
LPS disrupts the alveolar-capillary barrier, resulting in pulmonary vascular leak. However, little is known about the transcriptional events in endothelial cells that lead to the destabilization of the paracellular barrier under these conditions. We have recently shown that the transcription factor SOX18 protects the endothelial barrier against the disruptive effects of laminar shear stress by stimulating the expression of the tight junction protein claudin 5 (CLDN5) (7) . SOX18 belongs to the SRY (sex-determining region on the Y chromosome)-related HMG (high-mobility group) box group F family of transcription factors and plays a key role in blood vessel development. Interestingly, mutations in SOX18 cause cyanosis and superficial hemorrhage, as well as severe edema (8, 9) . Thus, we hypothesized that under conditions of ALI, SOX18 expression would be decreased and that the subsequent decrease in CLDN5 would potentially be involved in the increased pulmonary vascular leak in response to LPS.
Our data demonstrate that the SOX18-CLDN5 axis is decreased in two models of LPS-mediated ALI, with overexpression of SOX18 attenuating the severity of the lung injury induced by LPS challenge. Furthermore, we found that the mechanism by which LPS decreased SOX18 expression occurs via transcriptional repression and is mediated, at least in part, by the transcription factor NF-kB. Thus, our work identifies SOX18 as a new target in the complex regulation of lung vascular barrier function in response to gram-negative bacteria-dependent ALI.
Methods

Animal Studies
All animal housing protocols were approved by the institutional animal care and use committee in facilities accredited by American Association for the Accreditation of Laboratory Animal Care at Augusta University.
LPS-induced Lung Injury Models
Adult male C57BL/6NHsd mice (aged 7-8 wk; Harlan) were used in all experiments as described in the data supplement.
In vivo Overexpression of SOX18
The plasmids, pCMV6-SOX18 (40 mg) or DST-luciferase (40 mg), were incubated with glucose and jetPEI reagent (Polyplustransfection Inc.) as per the manufacturer's instructions for 15-30 minutes. Then, the DNA-jetPEI complexes were injected into mice via the tail vein as previously described (10) .
Cell Culture
Primary cultures of human lung microvascular endothelial cells (HLMVECs) were isolated as described previously (11) . Cells were cultured in M199 medium supplemented with 20% FBS, 100 U/ml heparin, 150 mg/ml endothelial cell growth factor, 1 mg/ml hydrocortisone, 292 mg/L L-glutamine, and 110 mg/L sodium pyruvate and maintained at 37 8 C in a humidifier with 5% CO 2 and 95% air. Cells were subcultured in a 1:3 ratio using standard techniques.
Transient Transfection of HLMVECs
HLMVECs were transfected with pCMV6-SOX18 plasmid or an NF-kB luciferase reporter assay plasmid using Effectene Transfection Reagent (Qiagen) or a Nucleofector 2b electroporator and the HLMVEC Nucleofector Kit (Lonza) according to the manufacturer's instructions.
siRNA-mediated Knockdown
HLMVECs were transfected with 20 nM of SOX18 or CLDN5 siRNA (Santa Cruz Biotechnology) with the use of HiPerFect Transfection Reagent (Qiagen) according to the manufacturer's instructions. A scrambled siRNA was used as a negative control. Validation of the gene-silencing effect was confirmed by immunoblot analysis. Additional methods used are described in the data supplement.
Statistical Analysis
Statistical analysis was performed using Prism version 4.01 software (GraphPad Software). The mean 6 SEM was calculated in all experiments, and statistical significance was determined by an unpaired t test (for two groups), one-way analysis of variance (for three or more groups) with Newman-Keuls post hoc testing, or two-way analysis of variance with Bonferroni post hoc testing. A value of P , 0.05 was considered significant.
Results
Expression of SOX18 and CLDN5 Are Reduced in a Mouse Model of ALI and in HLMVECs
A previous study showed that SOX18 expression is reduced in human umbilical vein endothelial cells by the proinflammatory mediators TNF-a, IL-1, and LPS (12) . Therefore, we hypothesized that LPS dysregulates SOX18 expression and that this mechanism is involved, at least in part, in the disruption of the endothelial barrier and edema formation in ALI. We first confirmed the downregulation of Sox18 at the mRNA ( Figure 1A ) and protein ( Figure 1B ) levels in the lungs of mice treated with LPS intraperitoneally for the indicated amount of time. In HLMVECs exposed to LPS (1 endotoxin unit [EU]/ml; 4 h), SOX18 mRNA ( Figure 1C ) and protein ( Figure 1D ) levels were similarly reduced. We have In vivo studies were conducted in which mice were treated with LPS (6.75 3 10 4 endotoxin units [EU]/g) intraperitoneally for up to 12 hours, and in vitro studies were performed using HLMVECs exposed to LPS (4 h; 1 EU/ml). Total RNA was isolated from LPS-treated mouse lungs and HLMVECs. (A and E) mRNA levels for Sox18 and Cldn5 were significantly decreased in mice treated with LPS compared with vehicle-treated mice, as determined by SYBR Green real-time RT-PCR analysis. Protein extracts prepared from lung tissue homogenates were subjected to immunoblot analysis and probed with anti-SOX18 or anti-CLDN5 antibodies. (B and F) Densitometric analysis indicated that SOX18 and CLDN5 protein levels were reduced in mice exposed to LPS. Furthermore, HLMVECs exposed to LPS for 4 hours had significantly lower (C and G) SOX18 and CLDN5 mRNA expression, as determined by SYBR Green real-time RT-PCR analysis, as well as (D and H) protein levels, as indicated by immunoblot analysis. (I) HLMVECs were exposed or not to LPS for 3 hours (1 EU/ml), and changes in paracellular and transcellular pathways were evaluated using immunofluorescence to detect (J and K) CLDN5, (L and M) vascular endothelial cadherin (VE-cadherin), (O and P) ZO-1, or (O and Q) CAV1. (L and N) Cells were also simultaneously stained with phalloidin and demonstrated an increase in gap formation. LPS decreased CLDN5 levels significantly. (L and M) Total VE-cadherin levels were unchanged, but the cell border localization was attenuated. LPS significantly decreased ZO-1 levels (O and P), but CAV1 levels were unchanged (O and Q). Values are mean 6 SEM; n = 4-6. Scale bars (panels L and O): 25 mm except in the right-hand panels, which are 5 mm. *P , 0.05 versus no LPS. CAV1 = caveolin 1; CLDN5 = claudin 5; SOX = SRY (sex-determining region on the Y chromosome)-related high-mobility group box; ZO-1 = zonula occludens 1. previously shown that SOX18 enhances endothelial barrier function by upregulating the tight junction protein CLDN5 in pulmonary arterial endothelial cells (7) . Thus, we next investigated whether the LPS-mediated downregulation of Sox18 affected CLDN5 levels in the mouse lung and in HLMVECs. Cldn5 mRNA expression ( Figure 1E ) and protein levels ( Figure 1F ) were significantly decreased in the lungs of mice treated with LPS compared with vehicle-treated mouse lungs. Similarly, in HLMVECs exposed to LPS (1 EU/ml) for 4 h, CLDN5 mRNA ( Figure 1G ) and protein ( Figure 1H ) levels were also reduced. Immunofluorescence analysis was used to evaluate changes in the paracellular and transcellular pathways ( Figure 1I ). The data indicate that LPS decreased CLDN5 levels significantly (Figures 1J and 1K) but did not change total VE-cadherin (CDH5) levels (Figures 1L and 1M). However, the expression pattern of VE-cadherin was altered whereby cell border expression was predominantly lost ( Figure 1L ). Simultaneous phalloidin staining identified a significant increase in gap formation ( Figures 1L and 1N ). Furthermore, LPS significantly reduced ZO-1 staining, indicating a loss of tight junction formation ( Figures 1O and 1P ). Immunofluorescence staining for caveolin 1 identified a nonsignificant increase, suggesting that transcellular transport was unaffected by LPS under these conditions compared with the paracellular pathway ( Figures 1I, 1O , and 1Q).
SOX18 Overexpression Prevents LPS-mediated Decrease in CLDN5 Protein Levels in HLMVECs
To evaluate the role of LPS-mediated SOX18 downregulation in endothelial cell permeability, we overexpressed the SOX18 transcription factor in HLMVECs exposed to LPS ( Figure 2A ) and found that SOX18 overexpression attenuated the LPS-induced decrease in endothelial barrier function ( Figure 2B ). Furthermore, overexpression of SOX18 in HLMVECs enhanced CLDN5 protein levels in the presence and absence of LPS ( Figure 2C ). To determine whether the protective effect of SOX18 overexpression on the endothelial barrier in the presence of LPS is mediated by CLDN5, SOX18 was overexpressed in HLMVECs before LPS exposure while CLDN5 expression was simultaneously silenced using a specific siRNA ( Figure 2D ). CLDN5 depletion in HLMVECs abolished the barrier-protective effect of SOX18 overexpression in the presence of LPS ( Figure 2E ). These findings suggest that LPS decreases SOX18 and CLDN5 levels, which in turn disrupts the endothelial barrier. In addition, the overexpression of SOX18 in an unrelated cell line (COS-7) is sufficient to increase CLDN5 promoter activity (see Figure E1 in the data supplement).
Gene Delivery of SOX18 to the Mouse Lung Attenuates Lung Permeability in ALI
To determine whether restoring SOX18 expression and enhancing CLDN5 levels can ameliorate the vascular hyperpermeability and lung damage in ALI, we used a polyethylenimine derivative transfection reagent to deliver pCMV6-SOX18 plasmid into the mouse lung via tail vein injection. Two days after gene delivery, mice received either saline (vehicle) or LPS (2 mg/kg) for 24 hours. Initial experiments confirmed a significant increase in SOX18 ( Figure 3A ) and CLDN5 ( Figure 3B ) protein levels in mouse lung in the presence and absence of LPS. Interestingly, overall SOX18 expression in the mouse lung in which SOX18 was overexpressed still declined after LPS exposure ( Figure 3A ), probably owing to the decrease in expression of endogenous SOX18. BAL fluid analysis indicated that SOX18 overexpression significantly attenuated LPS-induced cellular infiltration ( Figure 3C ) and protein extravasation ( Figure 3D ) into the lung airspaces. Using myeloperoxidase activity, we found that LPS-induced neutrophil infiltration was reduced in the lungs of SOX18-overexpressing mice ( Figure 3E ). In addition, we found that SOX18 overexpression significantly attenuated LPS-induced vascular leak, as indicated by a reduction in the extravasation of Evans Blue dye ( Figure 3F ). SOX18 overexpression did not appear to directly alter the expression of inflammation-related genes as determined using transcriptomewide scanning of gene expression patterns on an Affymetrix microarray platform ( Figure E2 ).
Gene Delivery of SOX18 to the Mouse Lung Prevents Lung Injury and Preserves Lung Mechanics in ALI
Lung sections stained with myeloperoxidase and hematoxylin and eosin indicated that increased SOX18 expression protected mouse lungs against LPS-induced histopathological changes characterized by edematous thickening of the alveolar septa, hyaline membrane formation, the infiltration of leukocytes, the presence of red blood cells in the alveolar and interstitial spaces, and debris accumulation in the alveoli ( Figure 4A) . A semiquantitative histopathological scoring system (13) was also used to assess the severity of the lung injury by evaluating the extent of intraalveolar neutrophil permeation, alveolar septal thickening, fibrin accumulation filling the airspaces, and the presence of hyaline membranes. SOX18 overexpression attenuated the Lung Injury Score in the LPS-treated mice ( Figure 4B ). An analysis of lung mechanics revealed that SOX18 overexpression prevented the LPS-induced downward displacement of the pressure-volume curve ( Figure 4C ). Finally, we found that SOX18 overexpression significantly improved lung mechanics, as indicated by increased lung compliance ( Figure 4D ), decreased lung elastance ( Figure 4E ), decreased lung resistance ( Figure 4F ), and higher oxygen saturation ( Figure 4G ).
NF-kB (p65) Is Recruited to the SOX18 Promoter and Decreases SOX18 Promoter Activity during LPS Exposure
To determine the mechanism by which LPS downregulates SOX18 expression, the SOX18 promoter (21,600 bp) was cloned into a pGL3 luciferase reporter vector ( Figure 5A ). Analysis of the SOX18 promoter sequence using MatInspector revealed two NF-kB (p50/p65) binding sites and one NF-kB (c-Rel/p65) binding site (defined as sites 1-3) (14) . After 48 hours of transfection with the SOX18 promoter construct, the HLMVECs were exposed to LPS (1 EU/ml) for 4 hours in the presence or absence of an NF-kB (p65) inhibitor, JSH-23 (4-methyl-N 1 -[3-phenylpropyl] benzene-1,2-diamine; 16 mM). LPS exposure decreased SOX18 promoter activity; however, the inhibition of NF-kB attenuated the LPS-mediated decrease in SOX18 promoter activity ( Figure 5B ). Chromatin immunoprecipitation (ChIP) analysis demonstrated that LPS promoted the binding of NF-kB (p65) to the endogenous SOX18 promoter at site 1 (21,082 to 21,073 bp upstream of 11) in HLMVECs ( Figure 5C ). Furthermore, the mutation of NF-kB binding site 1 from GGGAGCCTCC to CTCAGCCTTT abolished the LPS-dependent decrease in SOX18 promoter activity ( Figure 5D ).
NF-kB Activity Is Stimulated by Peroxynitrite during LPS Exposure
We have recently shown that reducing peroxynitrite generation can attenuate inflammatory signaling during LPS exposure (15) . Thus, we evaluated the role of peroxynitrite in stimulating NF-kB activity. We have previously shown that the nuclear factor of k light polypeptide gene enhancer in B cells inhibitor-a (IkBa) protein is susceptible to nitration at tyrosine (Y) 181 and Y 305 and that this reduces the ability of IkBa to negatively regulate NF-kB activity (16) data indicate that LPS stimulates the phosphorylation of p65 and that this is significantly reduced when peroxynitrite levels are decreased ( Figure 6B) . Similarly, peroxynitrite scavenging significantly attenuates the LPS-mediated activation of an NF-kB luciferase reporter promoter ( Figure 6C ), whereas exposing HLMVECs to a peroxynitrite donor alone is sufficient to increase the activity of the NF-kB luciferase reporter plasmid ( Figure 6D ).
Discussion
Our data show that SOX18 mRNA expression and protein levels are reduced in the mouse lung exposed to LPS, supporting the conclusion that LPS downregulates SOX18 expression via decreased transcription. In addition, we show in HLMVECs that SOX18 expression is reduced by LPS in an NF-kB (p65)-dependent manner. A previous study showed that SOX18 mRNA expression is reduced in human umbilical vein endothelial cells by the proinflammatory mediators TNF-a, IL-1, and LPS (12) . The TNF-a-induced decrease in SOX18 mRNA expression was similarly mediated by the p65 subunit of NF-kB (12) . Using several SOX18 promoter constructs of various lengths, it has been shown that the promoter region of SOX18 susceptible to TNF-a-mediated repression is located within 20.2 kb to 21.0 kb from the transcriptional start site (12) . We also found that the SOX18 promoter region responsible for LPS-induced, NF-kB (p65)-dependent repression is located within 21.6 kb of the transcriptional start site. Interestingly, whereas analysis of the SOX18 promoter using MatInspector revealed the presence of several potential NF-kB binding sites, ChIP analysis indicated that LPS increased NF-kB (p65) binding to the SOX18 promoter only at site 1 (21,082 to 21,073 bp upstream). Furthermore, the mutation of NF-kB (p65) binding site 1 prevented the LPS-mediated decrease in SOX18 promoter activity. ChIP analyses also identified a decrease in NF-kB binding to site 2. The significance of these data is unclear because mutating site 1 is sufficient to attenuate LPS-mediated decreases in SOX18 promoter activity. We speculate that there may be cooperativity between sites 1 and 2 in the regulation of SOX18 promoter activity. However, further studies are required to test this possibility.
NF-kB is an inducible transcription factor that binds to the decameric nucleotide sequence GGGACTTTCC (17) and regulates the expression of many genes involved in immune and inflammatory responses (18) . There are five NF-kB family members: p65 (RelA), RelB, c-Rel, p50 (NFkB1), and p52 (NF-kB2) (18) . The NF-kB subunits can homo-or heterodimerize through the Rel homology domain (19) . Although all NF-kB members are able to 
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bind DNA, only p65, RelB, and c-Rel have C-terminal transactivation domains (19) . The activity of NF-kB is regulated primarily through interactions with inhibitory IkB proteins. The best-studied NF-kB-IkB interaction is that of IkBa with the NF-kB p50-RelA (p65) dimer (20) . The presence of a nuclear export signal in IkBa results in the NF-kB complex being localized primarily to the cytoplasm, attenuating the ability of NF-kB to bind to DNA and regulate transcription. Thus, a key step in controlling the activity of NF-kB is regulating the IkB-NF-kB interaction.
In the classical or canonical pathway, activation of an IkB kinase complex leads to the serine phosphorylation of IkBa, targeting it for degradation (21) . The exposed NF-kB complex can then enter the nucleus and activate target gene expression. One of the target genes activated by NF-kB is IkBa (22) . This newly synthesized IkBa enters the nucleus and removes NF-kB bound to DNA. The complex is then exported back to the cytoplasm, and the original latent state is restored. In this manner, the activation of the NF-kB pathway is a highly regulated, transient process, lasting approximately 30-60 minutes in most cells (23, 24) . Our data suggest that nitration also activates NF-kB in a noncanonical manner. This is in agreement with our earlier studies . The overexpression of SOX18 in the mouse lung attenuates LPS-mediated lung injury and the disruption of lung mechanics. Mice were injected with either DST or SOX18 plasmid via the tail vein. After 48 hours, the mice received either saline (vehicle) or LPS (2 mg/kg body weight; 24 h) intratracheally. Lung sections were examined for signs of inflammation after hematoxylin and eosin staining ( A), neutrophil infiltration after MPO staining (A) (representative micrographs are shown), and scored for lung injury (B). The inflammatory response induced by LPS is reduced in SOX18-overexpressing mice, as indicated by (A) significantly less lung MPO staining and (B) a lower Lung Injury Score. Additional mice were anesthetized 24 hours after LPS exposure, and the area around the throat was shaved. Transcutaneous oxygen saturation was monitored via a pulse oximeter placed on the neck. Subsequently, the mice were intubated, connected to a flexiVent ventilator (SCIREQ), and then lung mechanics were assessed. (C) The analysis of dynamic pressure-volume relationships in the mouse lung indicated that LPS caused a displacement of the pressure-volume curve to lower lung volumes, which was attenuated in SOX18-overexpressing mice. These data show that, for a given amount of pressure, LPS-exposed, SOX18-overexpressing mice experienced a higher VT. The data represent pressure-volume loops for four groups with two curves: one for inhalation and one for exhalation events. SOX18-overexpressing mice given LPS also had (D) increased total respiratory compliance, (E) decreased total respiratory elastance, (F) decreased total respiratory resistance, and (G) higher oxygen saturation compared with LPS-exposed DST mice. Values are mean 6 SEM; n = 4-6. *P , 0.05 versus DST1vehicle; † P , 0.05 versus DST1LPS. H&E = hematoxylin and eosin; V T = tidal volume.
that demonstrated blocking protein nitration reduces inflammatory signaling mediated through NF-kB (10, 15, 25, 26) . The present study further demonstrates that NF-kB activation during LPS exposure is significantly attenuated (up to a 40% reduction) when peroxynitrite levels are reduced. Furthermore, our data suggest that the mechanism by which this occurs is via the nitration of IkBa at Y 305 . These data are in partial agreement with a prior study in which ionizing radiation stimulated NF-kB activity via IkBa nitration at Y 181 and Y 305 , leading to the dissociation from NF-kB (16) , although Y 181 nitration was not observed in LPS-challenged HLMVECs. The sustained activation of NF-kB in the lung during ARDS produces a so-called cytokine storm and a severe inflammatory response. The reasons for this prolonged activation are unresolved. However, nitration is a covalent modification that adds a nitro group to one ortho carbon of tyrosine's phenolic ring to form 3-nitrotyrosine. As such, the 3-nitrotyrosine group cannot be removed until the protein is degraded, resulting in loss of normal ORIGINAL RESEARCH physiological regulation. This is similar to that observed for NF-kB signaling during ARDS. Thus, although speculative, this could explain, at least in part, the aberrant temporal activation of NF-kB during ARDS and could potentially be a therapeutic target for treating the disease. Although NF-kB (p65) activation is typically associated with promoting transcription during ALI, recent reports suggest that NF-kB (p65) also functions as a transcriptional repressor under cytotoxic stimuli such as ultraviolet light (27) , doxorubicin (27) , and TNF-a (28) (29) (30) (31) (32) . Although the mechanism by which NF-kB-mediated transcriptional repression is not fully understood, available evidence suggests that epigenetic regulation via class I HDACs 1, 2, and 3 (27) and DNA (cytosine-5)-methyltransferase-1 (DNMT-1) (32) can be involved. Indeed, it is becoming more apparent that epigenetic regulation plays a major role in regulating gene expression under both physiologic and pathologic conditions. Acetylation is an important post-translational modification of histones determining the accessibility of chromatin and hence gene transcription (33) . It has been shown that NF-kB (p50, p65) interacts with HDAC1 through its p65/RelA domain (amino acids [aa] 1-276) to repress gene expression (34, 35) . In addition, p50 interacts directly with HDAC1 (34). Interestingly, protein kinase A (PKA), a barrier-protective signal, phosphorylates NF-kB (p65), lowering its affinity with HDAC1 (34) . HDAC2 is also recruited to NF-kB (p65) indirectly by binding to HDAC1 (35) . However, whether NF-kB induces the transcriptional repression of SOX18 via the recruitment of HDACs requires further study.
The regulation DNA methylation is another important epigenetic regulator of gene transcription. DNMT-1 is the most abundant DNA methyltransferase (36) . The DNMT family members are classified as either de novo (DNMT-3A and DNMT-3B) or maintenance (DNMT-1) (37). As part of the DNA replication complex, DNMT-1 maintains the DNA methylation pattern of the newly synthesized DNA strand via the addition of a methyl group to the 5 position of the cytosine ring within the CpG dinucleotides (C5-methylcytosine) (36) . DNA methylation is an important epigenetic modification that can become altered during disease states and lead to gene expression changes (37) . CpG islands are frequently located in the vicinity of transcriptional start sites, and the methylation of DNA may physically impede the binding of transcriptional factors to the gene (38) . In addition, methyl-CpG-binding domain proteins bind to methylated DNA and then recruit additional proteins, such as HDACs and other chromatin-remodeling proteins, to condense the chromatin structure (39) . The inflammatory cytokine TNF-a represses gene expression in cancerous lung cells by inducing an interaction between NF-kB (p65) and DNMT-1 (32) . The RelA domain (aa 109-119) of NF-kB (p65) was found to interact directly with DNMT-1 (32 . Peroxynitrite-mediated nitration is involved in the activation of NF-kB (p65) during LPS exposure in HLMVECs. HLMVECs were exposed to LPS (1 EU/ml) for 4 hours and IkBa (nuclear factor of k light polypeptide gene enhancer in B cells inhibitor, a) protein was immunoprecipitated and subjected to mass spectrometric analysis. (A) A single tyrosine residue located at tyrosine (Y) 305 was identified as being oxidized and nitrated. HLMVECs were also exposed to the peroxynitrite scavenger MnTMPyP (25 mM; 30 min pretreatment), then exposed to LPS (2 EU/ml) for 2 hours. (B) The level of NF-kB activation was then estimated by using immunoblot analysis to measure changes in phosphorylated p65 levels. LPS significantly increased phosphorylated p65 levels, and this was attenuated in the presence of MnTMPyP. HLMVECs were transiently transfected with a NF-kB luciferase reporter plasmid (48 h), then exposed to LPS (2 EU/ml; 8 h) or the peroxynitrite donor SIN-1 (1 mM) for 1 hour. (C and D) LPS significantly increased luciferase activity, and this was attenuated in the presence of MnTMPyP. Peroxynitrite alone is able to increase the activity of the NF-kB luciferase reporter plasmid. Values are mean 6 SEM; n = 3 (B-D). *P , 0.05 versus untreated; † P , 0.05 versus LPS alone. PTMs = post-translational modifications.
invasion of lung cancer cells (32) . Again, the possible role of DNMT-1 in the downregulation of SOX18 by LPS requires future studies.
Claudins are vital in the assembly of a tight junctional complex with CLDN5-knockout mice selectively permeable to small molecules (,800 kD), suggesting that the remaining claudins form slightly larger pores (40) . CLDN5 is dynamically regulated by several transcription factors. The present investigators (7) and others (41) have shown that CLDN5 expression and endothelial barrier function are increased by the transcription factor SOX18. However, other transcription factors can also regulate CLDN5. For example, a complex of T-cell factor 4, b-catenin, and Forkhead box protein O1 causes the repression of CLDN5 gene expression (42) , as does vascular endothelial growth factor (43) and TNF-a/NF-kB (44) . The expression of CLDN5 is upregulated by Krüppel-like factor 4 (45) and ETSrelated gene (46) . Thus, it is possible that in ALI, other transcription factors besides SOX18 may be involved in the downregulation of CLDN5. However, further studies are required to evaluate this possibility. CLDN5 can also be regulated in a post-translational manner. In particular, changes in its phosphorylation status can drastically regulate the barrier properties at the tight junction complex. For example, the secondary messenger cAMP induces the phosphorylation of CLDN5 on threonine residues via the activation of PKA, enhancing its membrane distribution and increasing endothelial barrier function (47) . The activation of PKC isoforms (PKC-a and -z) under inflammatory conditions increases CLDN5 serine phosphorylation and induces the disappearance of CLDN5 from the cell membrane, increasing endothelial permeability (48) . In addition, the Rho-associated protein kinase-mediated phosphorylation of CLDN5 on Thr 207 results in increased endothelial permeability (49) . Because RhoA/Rho-associated protein kinase signaling is enhanced by LPS, this could synergize with the loss of SOX18 to attenuate the barrier-protective effects of CLDN5.
In conclusion, our studies have identified a novel mechanism by which LPS attenuates pulmonary endothelial barrier function via the downregulation of the SOX18-CLDN5 axis. The fact that the gene delivery of SOX18 to the mouse lung attenuated the development of ALI in response to LPS challenge confirms the importance of this pathway in regulating the pulmonary endothelial barrier. Furthermore, these data, in conjunction with data derived from our earlier studies (7), implicate the SOX18-CLDN5 axis as a primary control point for endothelial paracellular permeability. This in turn influences inflammatory cell infiltration and transmigration, and when this axis is decreased, there is increased inflammatory lung injury and edema. Thus, we speculate that strategies aimed at augmenting the SOX18-CLDN5 pathway may be a new therapeutic approach to the treatment of ALI/ARDS. n
